Massachusetts Financial Services Co. MA Buys 5,498 Shares of Cencora, Inc. (NYSE:COR)

Massachusetts Financial Services Co. MA boosted its position in shares of Cencora, Inc. (NYSE:COR) by 0.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,197,159 shares of the company’s stock after acquiring an additional 5,498 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.61% of Cencora worth $269,457,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. New Millennium Group LLC bought a new position in shares of Cencora during the 2nd quarter worth about $26,000. LRI Investments LLC acquired a new stake in Cencora during the first quarter valued at approximately $31,000. MFA Wealth Advisors LLC bought a new stake in shares of Cencora in the 2nd quarter valued at approximately $30,000. Concord Wealth Partners acquired a new position in shares of Cencora in the 3rd quarter worth approximately $30,000. Finally, SYSTM Wealth Solutions LLC acquired a new position in shares of Cencora in the 2nd quarter worth approximately $36,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $245.02 on Friday. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business has a 50-day moving average of $233.12 and a 200-day moving average of $231.47. The stock has a market capitalization of $48.28 billion, a price-to-earnings ratio of 32.63, a PEG ratio of 1.60 and a beta of 0.44. Cencora, Inc. has a fifty-two week low of $195.83 and a fifty-two week high of $251.56.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be given a dividend of $0.55 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora’s payout ratio is 29.29%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. UBS Group raised their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Robert W. Baird lifted their price objective on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Wells Fargo & Company boosted their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $271.20.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now directly owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.